Bevacizumab in combination with irinotecan for patients with recurrent glioblastoma multiforme
Author:
Publisher
Springer Science and Business Media LLC
Subject
Oncology,General Medicine
Link
http://www.nature.com/articles/ncponc1077.pdf
Reference5 articles.
1. Vredenburgh JJ et al. (2007) Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 13: 1253–1259
2. Batchelor TT et al. (2007) AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11: 83–95
3. Pope WB et al. (2006) MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy. Neurology 66: 1258–1260
4. Chen W et al. (2007) Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study. J Clin Oncol 25: 4714–4721
5. Rubenstein JL et al. (2000) Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption. Neoplasia 2: 306–314
Cited by 11 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Glioblastoma update: molecular biology, diagnosis, treatment, response assessment, and translational clinical trials;F1000Research;2017-10-26
2. Molecularly Targeted Drugs Plus Radiotherapy and Temozolomide Treatment for Newly Diagnosed Glioblastoma: A Meta-Analysis and Systematic Review;Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics;2016-06-07
3. Molecular Biology in Pediatric High-Grade Glioma: Impact on Prognosis and Treatment;BioMed Research International;2015
4. Recurrent Glioblastoma Treated with Bevacizumab: Contrast-enhanced T1-weighted Subtraction Maps Improve Tumor Delineation and Aid Prediction of Survival in a Multicenter Clinical Trial;Radiology;2014-04
5. Management of treatment-associated toxicites of anti-angiogenic therapy in patients with brain tumors;Neuro-Oncology;2012-02-03
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3